These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30418046)

  • 21.
    Hou L; Li Y; Wang Y; Xu D; Cui H; Xu X; Cong Y; Yu C
    Dis Markers; 2018; 2018():4108919. PubMed ID: 30420903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma.
    Zhou M; Xu W; Yue X; Zhao H; Wang Z; Shi H; Cheng L; Sun J
    Oncotarget; 2016 May; 7(20):29720-38. PubMed ID: 27105492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma.
    Peng F; Wang R; Zhang Y; Zhao Z; Zhou W; Chang Z; Liang H; Zhao W; Qi L; Guo Z; Gu Y
    Mol Cancer; 2017 Jun; 16(1):98. PubMed ID: 28587642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of RCC2 Enhances Cell Motility and Promotes Tumor Metastasis in Lung Adenocarcinoma by Inducing Epithelial-Mesenchymal Transition.
    Pang B; Wu N; Guan R; Pang L; Li X; Li S; Tang L; Guo Y; Chen J; Sun D; Sun H; Dai J; Bai J; Ji G; Liu P; Liu A; Wang Q; Xiao S; Fu S; Jin Y
    Clin Cancer Res; 2017 Sep; 23(18):5598-5610. PubMed ID: 28606921
    [No Abstract]   [Full Text] [Related]  

  • 26. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
    Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
    Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a novel prognostic DNA methylation signature for lung adenocarcinoma based on consensus clustering method.
    Cai Q; He B; Xie H; Zhang P; Peng X; Zhang Y; Zhao Z; Wang X
    Cancer Med; 2020 Oct; 9(20):7488-7502. PubMed ID: 32860318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
    Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
    Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer.
    Micke P; Edlund K; Holmberg L; Kultima HG; Mansouri L; Ekman S; Bergqvist M; Scheibenflug L; Lamberg K; Myrdal G; Berglund A; Andersson A; Lambe M; Nyberg F; Thomas A; Isaksson A; Botling J
    J Thorac Oncol; 2011 Nov; 6(11):1833-40. PubMed ID: 22011649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a novel glycolysis-related gene signature that can predict the survival of patients with lung adenocarcinoma.
    Liu C; Li Y; Wei M; Zhao L; Yu Y; Li G
    Cell Cycle; 2019 Mar; 18(5):568-579. PubMed ID: 30727821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of diagnostic DNA methylation biomarkers specific for early-stage lung adenocarcinoma.
    Cai Q; Zhang P; He B; Zhao Z; Zhang Y; Peng X; Xie H; Wang X
    Cancer Genet; 2020 Aug; 246-247():1-11. PubMed ID: 32805686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer.
    Isobe H; Miyamoto H; Shimizu T; Haneda H; Hashimoto M; Inoue K; Mizuno S; Kawakami Y
    Cancer; 1990 Mar; 65(6):1391-5. PubMed ID: 2155055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of Na+-K+-2Cl- cotransporter isoform 1 (NKCC1) predicts poor prognosis in lung adenocarcinoma and EGFR-mutated adenocarcinoma patients.
    Sun PL; Jin Y; Park SY; Kim H; Park E; Jheon S; Kim K; Lee CT; Chung JH
    QJM; 2016 Apr; 109(4):237-44. PubMed ID: 26559081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer.
    Wu D; Xiong L; Wu S; Jiang M; Lian G; Wang M
    Lung Cancer; 2012 Apr; 76(1):106-11. PubMed ID: 21983100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
    BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel seven-long non-coding RNA signature predicts survival in early stage lung adenocarcinoma.
    Chen M; Liu B; Xiao J; Yang Y; Zhang Y
    Oncotarget; 2017 Feb; 8(9):14876-14886. PubMed ID: 28122330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
    Tian FM; Zhong CY; Wang XN; Meng Y
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2635-2641. PubMed ID: 28678321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
    Zhou S; Wang P; Su X; Chen J; Chen H; Yang H; Fang A; Xie L; Yao Y; Yang J
    PLoS One; 2017; 12(10):e0187356. PubMed ID: 29088286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High KIF2A expression promotes proliferation, migration and predicts poor prognosis in lung adenocarcinoma.
    Xie T; Li X; Ye F; Lu C; Huang H; Wang F; Cao X; Zhong C
    Biochem Biophys Res Commun; 2018 Feb; 497(1):65-72. PubMed ID: 29427669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma.
    Hwang JA; Song JS; Yu DY; Kim HR; Park HJ; Park YS; Kim WS; Choi CM
    Int J Clin Exp Pathol; 2015; 8(6):6627-35. PubMed ID: 26261544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.